---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020973"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:34:31.896744+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics reports zero clinically-relevant adverse events in Phase 1 single dose portion for PT00114

## Summary
- Phase 1 single dose trial completed with 30 subjects across five cohorts up to 1,000 micrograms; no clinically-relevant adverse events.
- Multiple ascending dose portion of the trial is planned to commence later this year.
- PT00114 targets stress reduction as root cause for PTSD, depression, anxiety, addiction, and potentially obesity.
- Investor call scheduled for May 22 at 10:00 am ET to discuss safety data and implications.

## SEC filing metadata
- accession: 0001493152-24-020973
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315224020973/0001493152-24-020973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315224020973/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020973
- JSON: https://secwatch.observer/filing/0001493152-24-020973.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.